NEW YORK and BOULDER — Pfizer Inc. (NYSE: PFE) has completed its $11 billion acquisition of Boulder-based oncology company Array BioPharma.
Approximately 77 percent of Array shares were tendered to Pfizer by the deadline last Friday, according to filings with the U.S. Securities and Exchange Commission, meeting the deal’s minimum requirements. Array’s stock, which was purchased at $48 per share by Pfizer, was delisted from the Nasdaq exchange at $47.85 per share Tuesday morning.
Array and Pfizer announced the deal on June 17.
“We are proud to bring Array’s exceptional scientific talent and broad pipeline into Pfizer,” said Pfizer chief scientific officer Mikael Dolsten in a prepared statement. “Combined with Pfizer’s leading research and development capabilities, today’s announcement strengthens our potential to translate advanced science and technologies into the breakthroughs that change patients’ lives.”
Pfizer spokeswoman Patricia Kelly said the company has no intention of reducing headcount at the former Array office or moving employees to other research sites across the country.
The deal also ends the chances of a handful of federal lawsuits filed by Array investors hoping to stop Pfizer’s acquisition. Three of the five suits that tried to halt the deal were voluntarily withdrawn, according to court records.
NEW YORK and BOULDER — Pfizer Inc. (NYSE: PFE) has completed its $11 billion acquisition of Boulder-based oncology company Array BioPharma.
Approximately 77 percent of Array shares were tendered to Pfizer by the deadline last Friday, according to filings with the U.S. Securities and Exchange Commission, meeting the deal’s minimum requirements. Array’s stock, which was purchased at $48 per share by Pfizer, was delisted from the Nasdaq exchange at $47.85 per share Tuesday morning.
Array and Pfizer announced the deal on June 17.
“We are proud to bring Array’s exceptional scientific talent and broad pipeline into Pfizer,” said Pfizer chief scientific officer Mikael Dolsten in a prepared statement. “Combined with Pfizer’s leading research and development capabilities, today’s announcement strengthens our potential to translate advanced science and technologies into the breakthroughs that change patients’ lives.”
Pfizer spokeswoman Patricia Kelly said the company has no intention of reducing headcount at the former Array office or moving employees to other research sites across the country.
The deal also ends the chances of a handful of federal lawsuits filed by Array investors hoping to stop Pfizer’s acquisition. Three of the five suits that tried to halt the deal were voluntarily withdrawn, according to court records.
…
This article has been intentionally blurred.
You must purchase a subscription to view the rest of this content.
Want to See More!?
OR
Start your subscription to BizWest, The Business Journal of the Boulder Valley and Northern Colorado, TODAY!
Print + Digital
$7/mo
billed monthly
- 1-month online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
- 1-month subscription to BizWest & all of the publications in print version.
Digital
$7/mo
billed monthly
- 1-month online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
Unlimited
$25/mo
billed annually
- 1-year online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
- 1-year subscription to BizWest & all of the publications in print version.
- 1-year premium online access to unlimited downloads from the BizWest Datastore!
Your promotional subscription will automatically renew at the full rate on the date of your subscription maturity. Reminder notices will be emailed before each auto-renewing payment to the email address on file. You may cancel at any time by calling (970) 232-3143 or emailing bdennis@bizwest.com. Your BizWest subscription also includes a complimentary subscription to the BizWest email newsletter, and you may easily unsubscribe from this at any time by emailing bdennis@bizwest.com.






